Trials Sponsors Conditions Drugs Pricing

Conditions

Breast Neoplasms Gene Expression Profiling Immunotherapy Neoplasm Metastasis

Keywords

Metastatic Breast NeoplasmsGene Expression Profilingimmunotherapy

Outcome Measures

Primary Outcomes (1)

immunotherapy response
Response of malignant pleural effusion to immunotherapy is evaluated with WHO guidelines
1 month

Secondary Outcomes (1)

immunological status
1 month

Study Arms (1)

cytokine

The patients are randomized to receive the cytokine infusion in the pleural cavity

Biological: cytokine

Interventions

cytokineBiological

interleukin 2 2 million unit every week

Also known as: interleukin 2 2 million unit every week

cytokine

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 75 Years

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

The breast cancer patiets present with pleural effusion and can receive chemotherapy.

You may qualify if:

Patients should be histologically confirmed with metastatic breast cancer and malignant pleural effusion

Sponsors & Collaborators

Peking University Cancer Hospital & Institute
Otherlead

Study Sites (1)

Beijing Cancer Hospital

Beijing, 100142, China

Biospecimen

Retention: SAMPLES WITHOUT DNA

The cancer cells are taken from the malignant pleural effusion of breast cancer patiets.

MeSH Terms

Conditions

Breast NeoplasmsNeoplasm Metastasis

Interventions

Cytokines

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Intercellular Signaling Peptides and Proteins

Study Officials

JUN REN, MD
Peking University Cancer Hospital & Institute
STUDY CHAIR

Enrollment

36 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Director

Study Record Dates

First Submitted

December 1, 2010

First Posted

December 9, 2010

Study Start

November 2010

Date type not reported

This date has not been verified as actual or estimated.

Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

cytokine

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

cytokine

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations